Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Clinical trial NCT05189067 · UNKNOWN
Trial details
- NCT number
- NCT05189067
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- UNKNOWN
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-31
- Primary completion
- 2025-01-31
- Enrollment
- 190
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.